The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
The ED50 as determined by the dose-dependent stimulation of the proliferation of Human MO7e cells is <10 ng/ml, corresponding to a specific activity of >1 x 105 units/mg.
% SDS-PAGE. Purity is greater than 98% as determined by HPLC and SDS-PAGE. Endotoxin Level: <0.1 ng/µg.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Store at -20°C. Store under desiccating conditions.
pH: 7.50 Constituent: 0.24% Tris
This product is an active protein and may elicit a biological response in vivo, handle with caution.
Reconstitute in H2O to a concentration of 0.1-1.0 mg/ml. This solution can then be diluted into other aqueous buffers. Reconstituted SCF should be stored in working aliquots at -20°C.
C kit ligand
familial progressive hyperpigmentation 2
Mast cell growth factor
MGF stem cell factor
Soluble KIT ligand
steel, mouse, homolog of
Stem cell factor
Stem cell factor precursor
Ligand for the receptor-type protein-tyrosine kinase KIT. Plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. KITLG/SCF binding can activate several signaling pathways. Promotes phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and subsequent activation of the kinase AKT1. KITLG/SCF and KIT also transmit signals via GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. KITLG/SCF and KIT promote activation of STAT family members STAT1, STAT3 and STAT5. KITLG/SCF and KIT promote activation of PLCG1, leading to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. KITLG/SCF acts synergistically with other cytokines, probably interleukins.
Involvement in disease
Hyperpigmentation with or without hypopigmentation, familial progressive Deafness, congenital, unilateral or asymmetric
Belongs to the SCF family.
Acts in the early stages of hematopoiesis.
A soluble form (sKITLG) is produced by proteolytic processing of isoform 1 in the extracellular domain. Found in two differentially glycosylated forms, LMW-SCF and HMW-SCF. LMW-SCF is fully N-glycosylated at Asn-145, partially N-glycosylated at Asn-90, O-glycosylated at Ser-167, Thr-168 and Thr-180, and not glycosylated at Asn-97 or Asn-118. HMW-SCF is N-glycosylated at Asn-118, Asn-90 and Asn-145, O-glycosylated at Ser-167, Thr-168 and Thr-180, and not glycosylated at Asn-97. A soluble form exists as a cleavage product of the extracellular domain.